Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

MLA

Atreya, R., et al. Cobitolimod for Moderate-to-Severe, Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Induction Trial. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1330710930&authtype=sso&custid=ns315887.

APA

Atreya, R., Peyrin-Biroulet, L., Klymenko, A., Augustyn, M., Bakulin, I., Slankamenac, D., Miheller, P., Gasbarrini, A., Hebuterne, X., Arnesson, K., Knittel, T., Kowalski, J., Neurath, M. F., Sandborn, W. J., Reinisch, W., & Gasbarrini A. (ORCID:0000-0002-7278-4823). (2020). Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.

Chicago

Atreya, R., L. Peyrin-Biroulet, A. Klymenko, M. Augustyn, I. Bakulin, D. Slankamenac, P. Miheller, et al. 2020. “Cobitolimod for Moderate-to-Severe, Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Induction Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1330710930&authtype=sso&custid=ns315887.